Table 2.
Clinical trials targeting CD47-based combination strategies in cancer.
| Agent targeting CD47 | Additional combinational regimen | Statusa | Phase | Condition | Sponsor | CT number |
|---|---|---|---|---|---|---|
| Chemotherapy | ||||||
| Magrolimab | Azacitidine | Recruiting | III | Myelodysplastic syndromes | Gilead Sciences | NCT04313881 |
| Magrolimab | Azacitidine | Recruiting | III | Acute myeloid leukemia | Gilead Sciences | NCT04778397 |
| Magrolimab | Docetaxel | Recruiting | II | Solid tumor | Gilead Sciences | NCT04827576 |
| Magrolimab | Pembrolizumab + 5-Fluorouracil + Platinum/b Docetaxel | Recruiting | II | Head and neck squamous cell carcinoma | Gilead Sciences | NCT04854499 |
| Magrolimab | Venetoclax + Azacitidine/Mitoxantrone + Etoposide + Cytarabine/CC-486 | Recruiting | II | Myeloid malignancies | Gilead Sciences | NCT04778410 |
| AK117 | Nab paclitaxel/Paclitaxel | Recruiting | II | Metastatic triple-negative breast cancer locally advanced triple-negative breast cancer | Akeso | NCT05227664 |
| TTI-621 | Doxorubicin | Recruiting | II | Leiomyosarcoma | Pfizer | NCT04996004 |
| Magrolimab | Azacitidine + Venetoclax | Recruiting | I/II | Acute myeloid leukemia recurrent acute myeloid leukemia refractory acute myeloid leukemia |
M.D. Anderson Cancer Center | NCT04435691 |
| Evorpacept | Azacitidine | Recruiting | I/II | Higher risk myelodysplastic syndromes | ALX Oncology Inc. | NCT04417517 |
| AK117 | Azacitidine | Recruiting | I/II | Myelodysplastic syndrome | Akeso | NCT04900350 |
| AK117 | Azacitidine | Recruiting | I/II | Acute myeloid leukemia | Akeso | NCT04980885 |
| Evorpacept | Venetoclax + Azacitidine | Active, not recruiting | I/II | Acute myeloid leukemia | ALX Oncology Inc. | NCT04755244 |
| AO-176 | Paclitaxel | Active, not recruiting | I/II | Solid tumor | Arch Oncology | NCT03834948 |
| Magrolimab | Azacitidine | Active, not recruiting | I | Hematological malignancies | Gilead Sciences | NCT03248479 |
| IBI188 | Azacitidine | Recruiting | I | Myelodysplastic syndromes | Innovent Biologics (Suzhou) Co., Ltd. | NCT04485065 |
| Lemzoparlimab | Azacitidine + Venetoclax/Azacitidine | Recruiting | I | Acute myeloid leukemia myelodysplastic syndrome | AbbVie | NCT04912063 |
| TTI-622 | Azacitidine/Azacitidine + Venetoclax | Recruiting | I | Lymphoma multiple myeloma acute myeloid leukemia |
Pfizer | NCT03530683 |
| DSP107 | Venetoclax + Azacitidine | Recruiting | I | Acute myeloid leukemia myelodysplastic syndromes chronic myelomonocytic leukemia |
Kahr Medical | NCT04937166 |
| IBI188 | Azacitidine | Suspended | I | Myelodysplastic syndromes | Innovent Biologics (Suzhou) Co., Ltd. | NCT04511975 |
| Targeted therapy | ||||||
| Evorpacept | Trastuzumab + Ramucirumab + Paclitaxel | Recruiting | II/III | Gastric cancer gastroesophageal junction adenocarcinoma gastric adenocarcinoma |
ALX Oncology Inc. | NCT05002127 |
| Magrolimab | Daratumumab | Recruiting | II | Multiple myeloma | Gilead Sciences | NCT04892446 |
| Magrolimab | Cetuximab | Completed | I/II | Solid tumor colorectal cancer | Gilead Sciences | NCT02953782 |
| Magrolimab | Rituximab/Rituximab + Gemcitabine + Oxaliplatin | Active, not recruiting | I/II | Non-Hodgkin lymphoma | Gilead Sciences | NCT02953509 |
| CC-90002 | Rituximab | Completed | I | Hematologic neoplasms | Celgene | NCT02367196 |
| Hu5F9-G4 | Acalabrutinib + Rituximab | Completed | I | Non-Hodgkin lymphoma diffuse large B cell lymphoma | Acerta Pharma BV | NCT03527147 |
| Magrolimab | Obinutuzumab + Venetoclax | Recruiting | I | Follicular lymphoma marginal zone lymphoma mantle cell lymphoma etc. |
National Cancer Institute | NCT04599634 |
| TG-1801 | Ublituximab | Recruiting | I | B-cell lymphoma | TG Therapeutics, Inc. | NCT03804996 |
| TG-1801 | Ublituximab | Recruiting | I | Chronic lymphocytic lymphoma small lymphocytic lymphoma follicular lymphoma etc. |
TG Therapeutics, Inc. | NCT04806035 |
| Magrolimab | Dinutuximab | Recruiting | I | High risk neuroblastoma recurrent neuroblastoma recurrent osteosarcoma etc. |
National Cancer Institute | NCT04751383 |
| TTI-621 | Rituximab | Active, not recruiting | I | Hematologic malignancies solid tumor | Pfizer | NCT02663518 |
| Lemzoparlimab | Pomalidomide + Dexamethasone/Daratumumab + Dexamethasone | Terminated (Strategic considerations) | I | Multiple myeloma | AbbVie | NCT04895410 |
| Immunotherapy | ||||||
| Evorpacept | Pembrolizumab + Platinum + 5-Fluorouracil |
Recruiting | II | Head and neck cancer head and neck squamous cell carcinoma | ALX Oncology Inc. | NCT04675333 |
| Magrolimab | Pembrolizumab | Recruiting | II | Head and neck squamous cell carcinoma | Gilead Sciences | NCT04854499 |
| Magrolimab | Pembrolizumab | Recruiting | II | Hodgkin lymphoma classic Hodgkin lymphomarelapsed classical hodgkin lymphoma, etc. | Stanford University | NCT04788043 |
| Evorpacept | Pembrolizumab | Recruiting | II | Head and neck cancer head and neck squamous cell carcinoma | ALX Oncology Inc. | NCT04675294 |
| Anti-CD47 antibody | SHR2150 | Recruiting | I/II | Solid tumor | Chinese PLA General Hospital | NCT04588324 |
| DSP107 | Atezolizumab | Recruiting | I/II | Advanced solid tumor non-small cell lung cancer | Kahr Medical | NCT04440735 |
| AO-176 | Pembrolizumab | Active, not recruiting | I/II | Solid tumor | Arch Oncology | NCT03834948 |
| Magrolimab | Avelumab | Completed | I | Ovarian cancer | Gilead Sciences | NCT03558139 |
| IBI188 | Sintilimab/GM-CSF | Recruiting | I | Solid tumors lung adenocarcinoma osteosarcoma |
Innovent Biologics (Suzhou) Co., Ltd. | NCT04861948 |
| Evorpacept | Pembrolizumab/Pembrolizumab + 5-Fluorouracil + Cisplatin | Active, not recruiting | I | Metastatic cancer solid tumor advanced cancer etc. |
ALX Oncology Inc. | NCT03013218 |
| TTI-621 | Nivolumab | Active, not recruiting | I | Hematologic malignancies solid tumor | Pfizer | NCT02663518 |
| Magrolimab | Mogamulizumab | Suspended (Other - Amendment Request) | I/II | Recurrent mycosis fungoides recurrent mycosis fungoides and sezary syndrome recurrent sezary syndrome etc. |
National Cancer Institute | NCT04541017 |
| TTI-621 | PD-1 or PD-L1 inhibitor/pegylated interferon-α2a/T-Vec/Radiation | Terminated | I | Solid tumors mycosis fungoides melanoma Merkel-cell carcinoma etc. |
Trillium Therapeutics Inc. | NCT02890368 |
| Bispecific antibody or fusion protein | ||||||
| HX009 | Active, not recruiting | II | Advanced solid tumor | Waterstone Hanxbio Pty Ltd. | NCT04886271 | |
| DSP107 | Recruiting | I/II | Advanced solid tumor non-small cell lung cancer | Kahr Medical | NCT04440735 | |
| CPO107 | Recruiting | I/II | Non-Hodgkin lymphoma | Conjupro Biotherapeutics, Inc. | NCT04853329 | |
| IBI322 | Recruiting | I | Hematologic malignancy | Innovent Biologics (Suzhou) Co., Ltd. | NCT04795128 | |
| IBI322 | Recruiting | I | Advanced malignancies | Innovent Biologics (Suzhou) Co., Ltd. | NCT04338659 | |
| IBI322 | Recruiting | I | Advanced malignancies | Innovent Biologics (Suzhou) Co., Ltd. | NCT04328831 | |
| PF-07257876 | Recruiting | I | Non-small cell lung cancer head and neck squamous cell carcinoma Ovarian cancer |
Pfizer | NCT04881045 | |
| IMM0306 | Recruiting | I | Non-Hodgkin lymphoma | ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. | NCT04746131 | |
| IMM2902 | Recruiting | I | Advanced solid tumor; advanced breast cancer; advanced gastric cancer | ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. | NCT05076591 | |
| TG-1801 | Recruiting | I | B-cell lymphoma | TG Therapeutics, Inc. | NCT03804996 | |
| IBI322 | Not yet recruiting | I | Advanced solid tumor | Innovent Biologics (Suzhou) Co., Ltd. | NCT04912466 | |
| HX009 | Active, not recruiting | I | Advanced solid tumor | Waterstone Hanxbio Pty Ltd. | NCT04097769 | |
| SG2501 | Not yet recruiting | I | Hematological malignancy lymphoma | Hangzhou Sumgen Biotech Co., Ltd. | NCT05293912 | |
| SL-172154 | Terminated (Sponsor decision) | I | Cutaneous squamous cell Carcinoma squamous cell Carcinoma of head and neck | Shattuck Labs, Inc. | NCT04502888 | |
a
Data from https://clinicaltrials.gov/ (collected on August 22, 2022).
b
“/” is used to distinguish the different study arms of the clinical trial.